Company: SXTPW
Filing Date: 2025-09-05
Form Type: 424B5
Source: 0001213900-25-085050
Chunk: 53

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-09-05
Form: 424B5
Chunk 53
---
| ● | Treatment of Chronic Tick-Borne Disease (Babesiosis).                                                                                        
 Babesia parasites are co-transmitted by the same ticks that transmit Borrelia, the Lyme disease bacterium. Although Lyme                     
 in the acute phase is generally viewed by the medical community as being treatable with antibiotics, individuals who are not treated,        
 or fail treatment, may go on to develop long term, and potentially debilitating, chronic symptoms such as fatigue, body aches, and cognitive 
 problems.1 This condition is defined by the Centers for Disease Control and Prevention (“CDC”) as Post-Treatment                             
 Lyme Disease Syndrome (“PTLDS”) or simply as Lyme in the patient community.2 Although there are no published estimates,                      
 key opinion leaders have stated that as many as 50% of Lyme/PTLDS patients are believed to be co-infected with Babesia parasites,            
 a diagnosis referred to in the Lyme community as “Chronic Babesiosis.” Prescribers in the Lyme disease community utilize a                   
 number of therapeutic modalities to manage the symptoms of Chronic Babesiosis, including FDA-approved pharmaceuticals such as atovaquone     
 and azithromycin (these are assumed to suppress the growth of Babesia parasites).3                                                           
 Recent market data shows that Tafenoquine appears                                                                                            
 to be increasingly prescribed by Lyme physicians to manage Chronic Babesiosis. This trend may follow the recent publication of several       
 case reports demonstrating activity in immunosuppressed patients with acute babesiosis, and animal data showing eradication of Babesia       
 parasites, Tafenoquine (primarily as Arakoda).4 The Company believes the recent increases in sales of Arakoda have been driven               
 by organic growth of these activities. There are no formal epidemiological publications articulating the incidence or prevalence of Chronic  
 Babesiosis, so these metrics must be inferred based on data for PTLDS and the rate of coinfection with Babesia parasites. Thus,              
 the cumulative case load of Chronic Babesiosis may be as high as1.01 million patients in the United States.5 We believe, based               
 on our market research that at least 37% of this market, or 375,000 cases, may be addressable with Tafenoquine during the remainder of       
 its market exclusivity window for malaria. We are undertaking additional research to determine how much additional market capture might      
 be feasible.                                                                                                                                 
 Acute infection with many different organisms (e.g. Borrelia,